公开(公告)号：EP2172222A3

公开(公告)日：2010-06-23

申请号：EP10150486.8

申请日：2005-04-25

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Nakade, Shinji ,  Shouno, Tomoyuki ,  Shimizu, Takao ,  Yokomizo, Takehiko ,  Iizuka, Yoshiko

IPC分类号： A61K45/00 ,  A61K31/192 ,  A61K31/4402 ,  A61P1/16 ,  A61P9/10 ,  A61P17/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00

CPC分类号： C07D213/38 ,  A61K31/192 ,  A61K31/4402 ,  C07C229/38 ,  C07C233/47 ,  C07C233/51 ,  C07C233/63 ,  C07C233/87 ,  C07C235/52 ,  C07C255/58 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/42

摘要： [PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed.
[MEANS] FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I)

, salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.

摘要翻译： [问题]需要选择性结合BLT2的化合物和用于BLT2介导的疾病如皮肤病的预防和/或治疗药物。 解决问题的手段本发明提供具有BLT2结合活性的化合物，其盐，其溶剂合物或其前药。 由于具有BLT2结合活性的化合物，特别是由式（I）表示的化合物，其盐，其溶剂合物或其前药（式中的符号与说明书同义）具有BLT2结合活性，因此可用于预防和 /或BLT2介导的疾病的治疗，例如皮肤病，肠道疾病，HIV感染，获得性免疫缺陷综合征，移植排斥反应，移植排斥反应，移植物抗宿主病，自身免疫性疾病，过敏性疾病，炎症，感染，溃疡，淋巴瘤， 恶性肿瘤，白血病，动脉硬化，肝炎，肝硬化或癌症等。

公开(公告)号：EP2172222A2

公开(公告)日：2010-04-07

申请号：EP10150486.8

申请日：2005-04-25

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Nakade, Shinji ,  Shouno, Tomoyuki ,  Shimizu, Takao ,  Yokomizo, Takehiko ,  Iizuka, Yoshiko

IPC分类号： A61K45/00 ,  A61K31/192 ,  A61K31/4402 ,  A61P1/16 ,  A61P9/10 ,  A61P17/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00

CPC分类号： C07D213/38 ,  A61K31/192 ,  A61K31/4402 ,  C07C229/38 ,  C07C233/47 ,  C07C233/51 ,  C07C233/63 ,  C07C233/87 ,  C07C235/52 ,  C07C255/58 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/42

摘要： [PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed.
[MEANS] FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I)

, salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.

摘要翻译： [问题]需要选择性结合BLT2的化合物和BLT2介导的疾病如皮肤疾病的预防和/或治疗药物。 解决问题的手段]本发明提供了具有BLT2结合活性的化合物，其盐，其溶剂合物或前药。 由于具有BLT2结合活性的化合物，特别是由式（I）表示的化合物，其盐，其溶剂合物或其前药（式中的符号具有与说明书相同的含义）具有BLT2结合活性，因此用于预防和 /或治疗BLT2介导的疾病，例如皮肤病，肠疾病，HIV感染，获得性免疫缺陷综合征，移植排斥反应，移植排斥反应，移植物抗宿主病，自身免疫疾病，变应性疾病，炎症，感染，溃疡，淋巴瘤， 恶性肿瘤，白血病，动脉硬化，肝炎，肝硬化或癌症等。